$0.58
(Market cap
$9 Mln
Recently Viewed
Clear AllMarket cap
$9 Mln
Revenue (TTM)
$0 Mln
P/E Ratio
--
P/B Ratio
0.5
Div. Yield
0 %
Today’s Range
52 Week Range
Liquidity
Net Profit (TTM)
$-3 Mln
ROE
-0.6 %
ROCE
-- %
Industry P/E
--
EV/EBITDA
1.6
Debt to Equity
0
Book Value
$--
EPS
$-4104.2
Face value
--
Shares outstanding
2,040,290
CFO
$-106.57 Mln
EBITDA
$-105.05 Mln
Net Profit
$-143.70 Mln
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
Diffusion Pharmaceuticals (DFFN)
| 21.9 | 73.5 | 105.5 | 11.2 | -47.3 | -53.8 | -59.2 |
|
BSE Sensex*
| -9.5 | 5.5 | -6.0 | -4.3 | 8.7 | 9.9 | 11.5 |
|
S&P Small-Cap 600#
| -5.8 | -5.3 | -13.7 | -6.3 | 5.3 | 3.0 | 5.5 |
|
Company
|
2021
|
2020
|
2019
|
2018
|
2017
|
2016
|
2015
|
|---|---|---|---|---|---|---|---|
|
Diffusion Pharmaceuticals (DFFN)
| -61.0 | 72.6 | -76.8 | -88.6 | -47.8 | -77.4 | -69.7 |
|
S&P Small-Cap 600
| 25.3 | 9.6 | 20.9 | -9.7 | 11.7 | 24.7 | -3.4 |
|
BSE Sensex
| 22.0 | 15.8 | 14.4 | 5.9 | 27.9 | 1.9 | -5.0 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Diffusion Pharmaceuticals Inc., a biopharmaceutical company, develops novel therapies that enhance the body's ability to deliver oxygen. Its lead product candidate is Trans Sodium Crocetinate that is developed to enhance the diffusion of oxygen to... tissues, as well as to treat COVID-19 disease. The company was founded in 2001 and is based in Charlottesville, Virginia. Read more
Pres, CEO & Director
Dr. Robert J. Cobuzzi Jr., Ph.D.
Pres, CEO & Director
Dr. Robert J. Cobuzzi Jr., Ph.D.
Headquarters
Charlottesville, VA
Website
Our rating system has guided millions of investors in the past 20 years.
The share price of Diffusion Pharmaceuticals Inc (DFFN) is $9.25 (NASDAQ) as of 18-Oct-2023 09:30 EDT. Diffusion Pharmaceuticals Inc (DFFN) has given a return of -47.32% in the last 3 years.
Since, TTM earnings of Diffusion Pharmaceuticals Inc (DFFN) is negative, P/E ratio is not available.
The P/B ratio of Diffusion Pharmaceuticals Inc (DFFN) is 0.51 times as on 18-Oct-2023, a 89 discount to its peers’ median range of 4.57 times.
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
|
2022
|
-0.68
|
0.51
|
|
2021
|
-0.03
|
0.02
|
|
2020
|
-0.07
|
0.04
|
|
2019
|
-0.03
|
0.02
|
|
2018
|
-0.01
|
0.01
|
The 52-week high and low of Diffusion Pharmaceuticals Inc (DFFN) are Rs -- and Rs -- as of 25-Apr-2026.
Diffusion Pharmaceuticals Inc (DFFN) has a market capitalisation of $ 9 Mln as on 18-Oct-2023. As per SEBI classification, it is a Small Cap company.
Before investing in Diffusion Pharmaceuticals Inc (DFFN), assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.